The role of PET in presurgical assessment of partial epilepsies

Epileptic Disorders

Volumn 6, Issue 3, 2004, Pages 193-215

  Mauguière, François ^a   Ryvlin, Philippe ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

18FDG; Epilepsy surgery; Partial epilepsies; PET; Presurgical evaluation

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; FLUORODEOXYGLUCOSE F 18; OPIATE RECEPTOR; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SEROTONIN RECEPTOR;

DIAGNOSTIC VALUE; EPILEPTIC FOCUS; FOCAL EPILEPSY; GLUCOSE METABOLISM; HUMAN; ISOTOPE LABELING; NERVE EXCITABILITY; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW;

BRAIN CHEMISTRY; EPILEPSIES, PARTIAL; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LIGANDS; NEUROSURGICAL PROCEDURES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, GABA-A;

EID: 4544281247     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (193)

1. Sokoloff L. Measurement of local cerebral glucose utilization and its relation to local functional activity in the brain. Adv Exp Med Biol 1991; 291: 21-42.
2. Phelps ME, Huang SC, Hoffman EJ, Salin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F 18)2-fluoro-2-deoxy-D-glucose: Validation of method. Ann Neurol 1979; 6: 371-88.
3. Meltzer CC, Adelson PD, Brenner RP, et al. Planned ictal FDG PET imaging for localization of extratemporal epileptic foci. Epilepsia 2000; 41: 193-200.
4. Henry TR, Chugani HT, Abou-Khalil BH, Theodore WH, Swartz BE. Positron emission tomography. In: Engel J (Ed), Surgical treatment of the epilepsies. Second Edition, New York, Raven Press, 1993, p. 211-32.
5. Leiderman DB, Balish M, Bromfield EB, Theodore WH. Effect of valproate on human cerebral glucose metabolism. Epilepsia 1991; 32: 417-22.
6. Gaillard WD, Fazilat S, White S, et al. Interictal metabolism and blood flow are uncoupled in temporal lobe cortex of patients with complex partial seizures. Neurology 1995; 45: 1841-7.
7. Lee DS, Lee JS, Kang KW, Jang MJ, Lee SK, Chung JK, Lee MC. Disparity of perfusion and glucose metabolism of epileptogenic zones in temporal lobe epilepsy demonstrated by SPM/SPAM analysis on 150 water PET, [18F]FDG-PET, and [99mTc]-HMPAO SPECT. Epilepsia 2001; 42: 1515-22.
8. Franck G, Sadzot B, Salmon E, et al. Regional cerebral blood flow and metabolic rates in human focal epilepsy ans status epilepticus. In: Delgado-Escueta AV, Ward Jr AA, Woodbury DM, Porter RJ (Eds), Basic Mechanisms of the Epilepsies. Molecular and Cellular Approaches Advances in Neurology, Volume 44, Raven Press, New-York, 1986, p. 935-48.
9. Theodore WH, Balish M, Leiderman D, Bromfield E, Sato S, Herscovitch P. Effect of seizures on cerebral blood flow measured with 150-H20 and positron emission tomography. Epilepsia 1996; 37: 796-802.
10. 2O PET study of cerebral blood flow changes during focal epileptic discharges induced by intracerebral electrical stimulation. Brain 1999; 122: 1851-65.
11. Delforge J, Syrota A, Mazoyer B. Design optimization: theory and application to estimation of receptor model parameters using dynamic positron emission tomography. Phys Med Biol 1989; 34: 419-35.
12. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993; 13: 15-23.
13. Savic I, Ingvar M, Stone Elander S. Comparison of [(11)C]flumazenil and [(18)F] FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry 1993; 56: 615-21.
14. 123I-iomazenil SPECT in presurgical evaluation of temporal lobe epilepsy? J Neurol Neurosurg Psychiatr 1997; 62: 141-50.
15. Ryvlin P, Bouvard S, Le Bars D, et al. Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients. Brain 1998; 121: 2067-81.
16. Henry TR, Frey KA, Sackellares JC, et al. In vivo cerebral metabolism and central benzodiazepine receptor binding in temporal lobe epilepsy. Neurology 1993; 43: 1998-2006.
17. Koepp MJ, Richardson MP, Brooks DJ, et al. Cerebral benzodiazepine receptors in hippocampal sclerosis: An objective in vivo analysis. Brain 1996; 119: 1677-87.
18. 11C-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy. Neurology 1997; 49: 764-73.
19. 11C]flumazenil PET in temporal lobe epilepsy with unilateral and bilateral hippocampal sclerosis. Brain 1997; 120: 1865-76.
20. Richardson MP, Koepp MJ, Brooks DJ, Fish DR, Duncan JS. Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: An 11C-Flumazenil PET study. Ann Neurol 1996; 40: 188-98.
21. Szelies B, Weber-Luxenburger G, Pawlik G, et al. MRI-guided flumazenil- and FDG-PET in temporal lobe epilepsy. Neuroimage 1996; 3: 109-18.
22. Millet P, Delforge J, Mauguiere F, et al. Parameter and index images of benzodiazepine receptor concentration in the brain. J Nucl Med 1995; 36: 1462-71.
23. Koepp MJ, Hand KS, Labbe C, et al. In vivo [11C]flumazenil-PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis. Ann Neurol 1998; 43: 618-26.
24. Savic I, Roland P, Sedvall G, Persson A, Pauli S, Widen L. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 1988; 8616: 863-6.
25. Burdette DE, Sakurai SY, Henry TR, et al. Temporal lobe central benzodiazepine binding in unilateral mesial temporal lobe epilepsy. Neurology 1995; 45: 934-41.
26. Savic I, Thorell JO, Roland P. [(11)C]flumazenil positron emission tomography visualizes frontal epileptogenic regions. Epilepsia 1995; 36: 1225-32.
27. Caldecott-Hazard S, Ackermann RF, Engel Jr J. Opioid involvement in postictal and interictal changes in behavior. In: Fariello RG, Morselli PL, Lloyd K, Quesney LF, Engel Jr J (Eds.), Neurotransmitters, Seizures and Epilepsy II. Raven Press, New-York, 1984, p. 305-14.
28. Engel Jr J, Ackermann RF, Caldecott-Hazard S, Chugani HT. Do altered opioid mechanisms play a role in human epilepsy? In: Fariello RG, Morselli PL, Lloyd K, Quesney LF, Engel Jr J (eds.), Neurotransmitters, Seizures and Epilepsy II. Raven Press, New-York, 1984, p. 263-74.
29. Bajorek JG, Lee RJ, Lomax P. Neuropeptides: anticonvulsant and convulsant mechanisms in epileptic model systems and in humans. Adv Neurol 1986; 44: 489-500.
30. Tortella FC. Endogenous opiod peptides and epilepsy: quieting the seizing brain? Trends Pharmacol Sci 1988; 9: 36-72.
31. Ranabadran K, Bansinath M. Endogenous opiod peptides and epilepsy. Int J Clin Pharmacol Ther Toxicol 1990; 28: 47-62.
32. Cheng JG, Xie XK. A study of opioid peptides in CSF of patients with epilepsy. Epilepsy Res 119; 6, 141-145.
33. Frost JJ, Mayberg HS, Fisher RS, et al. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol 1988; 23: 231-7.
34. Frost JJ, Mayberg HS, Sadzot B, et al. Comparison of 11C-diprenorphine and 11C-carfentanil binding to opiate receptors in man by positron emission tomography. J Cereb Blood Flow Metab 1990; 10: 484-92.
35. Mayberg HS, Sadzot B, Meltzer CC, et al. Quantification of mu and non mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Ann Neurol 1991; 30: 3-11.
36. Theodore WH, Carson RE, Andreasen P, et al. PET imaging of opiate receptor binding in human epilepsy using [(18)F]cyclofoxy. Epilepsy Res 1992; 13: 129-39.
37. Madar I, Lesser RP, Krauss G, et al. Imaging of delta- and mu-opiod receptors in temporal lobe epilepsy by positron emission tomography. Ann Neurol 1997; 41: 358-67.
38. Koepp MJ, Richardson MP, Brooks DJ, Duncan JS. Focal release of endogenous opiods during reading-induced seizures. Lancet 1998; 352: 952-5.
39. Peroutka SJ. 5-HT receptors: past, present and future. Trends Neurosci 1995; 18: 68-9.
40. Gerber K, Filakovszky J, Halasz P, Bagdy G. The 5-HT1A agonist 8-OH-DPAT increases the number of spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res 1998; 807: 243-5.
41. Filakovszky J, Gerber K, Bagdy G. A serotonin-1A receptor agonist and an N-methyl-D-aspartate receptor antagonist oppose each others effects in a genetic rat epilepsy model. Neurosci Lett 1999; 261: 89-92.
42. Lerner-Natoli M. Serotonin and kindling development. Int J Neurosci 1987; 36: 139-51.
43. Wada Y, Nakamura M, Hasegawa H, Yamaguchi N. Role of serotonin receptor subtype in seizures kindled from the feline hippocampus. Neurosci Lett 1992; 141: 21-4.
44. Wada Y, Shiraishi J, Nakamura M, Koshino Y. Role of serotonin receptor subtypes in the development of amygdaloid kindling in rats. Brain Res 1997; 747: 338-42.
45. Gariboldi M, Tutka P, Samanin R, Vezzani A. Stimulation of 5-HT1A receptors in the dorsal hippocampus and inhibition of limbic seizures induced by kainic acid in rats. Br J Pharmacol 1996; 119: 813-8.
46. Salgado-Commissariat D, Alkadhi KA. Serotonin inhibits epileptiform discharge by activation of 5-HT1A receptors in CA1 pyramidal neurons. Neuropharmacology 1997; 36: 1705-12.
47. Tokarski K, Zahorodna A, Bobula B, Hess G. Comparison of the effects of 5-HT1A and 5-HT4 receptor activation on field potentials and epileptiform activity in rat hippocampus. Exp Brain Res 2002; 147: 505-10.
48. Trottier S, Evrard B, Vignal JP, Scarabin JM, Chauvel P. The serotonergic innervation of the cerebral cortex in man and its changes in focal cortical dysplasia. Epilepsy Res 1996; 25: 79-106.
49. Favale E, Rubino V, Mainardi P, Lunardi G, Albano C. Anti-convulsant effect of fluoxetine in humans. Neurology 1995; 45: 1926-7.
50. Gunn RN, Sargent PA, Bench CJ, et al. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 1998; 8: 426-40.
51. Lang L, Jagoda E, Schmall B, et al. Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem 1999; 42: 1576-86.
52. Le Bars D, Lemaire C, Ginovart N, et al. High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. Nucl Med Biol 1998; 25: 343-50.
53. Zimmer L, Mauger G, Le Bars D, Bonmarchand G, Luxen A, Pujol JF. Effect of endogenous serotonin on the binding of the 5-hT1A PET ligand 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis. J Neurochem 2002; 80: 278-86.
54. Costes N, Merlet I, Zimmer L, Lavenne F, et al. Modeling [18 F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection. J Cereb Blood Flow Metab 2002; 22: 753-65.
55. Toczek MT, Carson RE, Lang L, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003; 60: 749-56.
56. Merlet I, Ryvlin P, Costes N, et al. Statistical parametric mapping of 5HT1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG. Neuroimage 2004; 22: 886-96.
57. Merlet I, Ostrowsky K, Costes N, et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: A [18F]MPPF-PET study. Brain 2004; 127: 900-13.
58. Chugani DC, Chugani HT, Muzik O, et al. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography. Ann Neurol 1998; 44: 858-66.
59. Fedi M, Reutens DC, Andermann F, et al. Alpha-[11C]-Methyl-L-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency. Epilepsy Res 2003; 52: 203-13.
60. Fedi M, Reutens D, Okazawa H, et al. Localizing value of alpha-methyl-L-tryptophan PET in intractable epilepsy of neocortical origin. Neurology 2001; 57: 1629-36.
61. Juhasz C, Chugani DC, Muzik O, et al. Alpha-methyl-L-tryptophan PET detects epileptogenic cortex in chidren with intractable epilepsy. Neurology 2003; 60: 960-8.
62. Natsume J, Kumakura Y, Bernasconi N, et al. Alpha-[11C] methyl-L-tryptophan and glucose metabolism in patients with temporal lobe epilepsy. Neurology 2003; 60: 756-61.
63. Lapin IP, Prakhie IB, Kiselva IP. Excitatory effects of kynurenine and its metabolites, amino acids and convulsants administered into brain ventricles: differences between rats and mice. J Neural Transm 1982; 54: 229-38.
64. Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 1982; 247: 184-7.
65. Rosenow F, Lüders H. Presurgical evaluation of epilepsy. Brain 2001; 124: 1683-700.
66. Kuhl D, Engel Jr J, Phelps ME, Selin C. Epileptic patterns of local cerebral metabolism and perfusion in humans, determined by emission computed tomography of 18FDG and 13NH3. Ann Neurol 1980: 348-60.
67. Barrington SF, Koutroumanidis M, Agathonikou A, et al. Clinical value of 18F fluorodeoxyglucose positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia 1998; 39: 753-66.
68. Engel Jr J, Kuhl DE, Phelps ME, Mazziotta JC. Interictal cerebral glucose metabolism in partial epilepsy and its relation to E.E.G changes. Ann Neurol 1982; 12: 510-7.
69. Kessler RM, Margolin R, Manning R, Channing M, Porter RJ. 18F fluorodeoxyglucose positron emission tomography in refractory complex partial seizures. Ann Neurol 1983; 14: 429-37.
70. Engel Jr J, Henry TR, Risinger MW, et al. Presurgical evaluation for partial epilepsy: relative contributions of chronic depth electrode recordings versus FDG PET and scalp sphenoidal ictal EEG. Neurology 1990; 40: 1670-7.
71. Theodore WH, Katz D, Kufta C, Sato S, Patronas N, Smothers P, Bromfield E. Pathology of temporal lobe foci: correlation with CT, MRI, and PET. Neurology 1990; 40: 797-803.
72. Stefan H, Pawlik G, Bocher Schwarz HG, et al. Functional and morphological abnormalities in temporal lobe epilepsy: a comparison of interictal and ictal EEG, CT, MRI, SPECT and PET. J Neurol 1987; 234: 377-84.
73. Ryvlin P, Philippon B, Cinotti L, Froment JC, Le Bars D, Mauguiere F. Functional neuroimaging strategy in temporal lobe epilepsy: a comparative study of 18FDG-PET and 99mTc-HMPAO-SPECT. Ann Neurol 1992; 31: 650-6.
74. Andersen AR, Rogvi-Hansen B, Dam M. Utility of interictal SPECT of rCBF for focal diagnosis of the epileptogenic zone(s). Acta Neurol Scand 1994; 89(Suppl. 152):129-34.
75. Fink GR, Pawlik G, Stefan H, Pietrzyk U, Wienhard K, Heiss WD. Temporal lobe epilepsy: evidence for interictal uncoupling of blood flow and glucose metabolism in temporomesial structures. J Neurol Sci 1996; 137: 28-34.
76. Theodore WH, Brooks RD, Patronas N, et al. The effect of phenobarbital and phenytoin on cerebral glucose metabolism measured by positron emission tomography. Neurology 1984; 34: S118.
77. Theodore WH, Dorwart R, Holmes M, Porter RJ, Di Chiro G. Neuroimaging in refractory partial seizures: Comparison of PET, CT, and MRI. Neurology 1986; 36: 750-9.
78. Theodore WH, Sato S, Kufta C, Balish MB, Bromfield EB, Leiderman DB. Temporal lobectomy for uncontrolled seizures: The role of positron emission tomography. Ann Neurol 1992; 32: 789-94.
79. Theodore WH, Fishbein D, Dubinsky R. Patterns of cerebral glucose metabolism in patients with partial seizures. Neurology 1988; 38: 1201-6.
80. Ryvlin Ph, Cinotti L, Froment JC, et al. Metabolic patterns associated with non-specific resonance imaging abnormalities in temporal lobe epilepsy. Brain 1991; 114: 2363-83.
81. Ryvlin P, Mauguière F, Sindou M, Froment JC, Cinotti L. Interictal cerebral metabolism and epilepsy in cavernous angiomas. Brain 1995; 118: 677-87.
82. Henry TR, Mazziotta JC, Engel Jr J. Interictal metabolic anatomy of mesial temporal lobe epilepsy. Arch Neurol 1993; 50: 582-9.
83. Henry TR, Sutherling WW, Engel Jr J, et al. Interictal cerebral metabolism in partial epilepsies of neocortical origin. Epilepsy Res 1991; 10: 174-82.
84. Henry TR, Mazziotta JC, Engel Jr J. The functional anatomy of frontal lobe epilepsy studied with PET. In: Chauvel P, Delgado-Escueta AV, Halgren E, Bancaud J (eds.), Advances in Neurology. Vol 57, Frontal lobe seizures and epilepsies, Raven Press, New-York, 1992, p. 487-97.
85. Sperling MR, Wilson G, Engel Jr J, Babb TL, Phelps M, Bradley W. Magnetic resonance imaging in intractable partial epilepsy: correlative studies. Ann Neurol 1986; 20: 57-62.
86. Hajek M, Antonini A, Leenders KL, Wieser HG. Mesiobasal versus lateral temporal lobe epilepsy: Metabolic differences in the temporal lobe shown by interictal (18)F FDG positron emission tomography. Neurology 1993; 43: 79-86.
87. Sadzot B, Debets RMC, Maquet P, et al. Regional brain glucose metabolism in patients with complex partial seizures investigated by intracranial EEG. Epilepsy Res 1992; 12: 121-9.
88. Swartz BE, Halgren E, Delgado-Escueta AV, et al. Neuroimaging in patients with seizures of probable frontal lobe origin. Epilepsia 1989; 30: 547-58.
89. Swartz BE, Theodore WH, Sanabria E, Fischer RS. Positron emission and single photon computed tomographic studies in the frontal lobe with emphasis on the relationship to seizure foci. In: Chauvel P, Delgado-Escueta A, Halgren E, Bancaud J (eds), Advances in Neurology, Vol 57, Frontal lobe seizures and epilepsies, Raven Press, New-York, 1992, p. 487-97.
90. Swartz BE, Khonsari A, Brown C, Mandelkern M, Simpkins F, Krisdakumtorn T. Improved sensitivity of 18FDG-positron emission tomography scans in frontal and "frontal plus" epilepsy. Epilepsia 1995; 36: 388-95.
91. Franck G, Maquet P, Sadzot B, et al. Contribution of Positron Emission Tomography to the investigation of epilepsies of frontal lobe origin. In: Chauvel P, Delgado-Escueta AV, Halgren E, Bancaud J (eds.), Advances in Neurology, Vol 57, Frontal lobe seizures and epilepsies, Raven Press, New-York, 1992 p. 471-85.
92. Da Silva EA, Chugani D, Muzik O, Chugani HT. Identfication of frontal lobe epileptic foci in children using positron emission tomography. Epilepsia 1997; 38: 1198-208.
93. Drzezga A, Arnold S, Minoshima S, et al. 18-FDG PET in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 1999; 40: 737-46.
94. Kim YK, Lee DS, Chung CK, Chung JK, Lee MC. 18F-FDG PET in localization of frontal lobe epilepsy: comparison of visual and SPM analysis. J Nucl Med 2002; 43: 1167-74.
95. Franceschi M, Lucignani G, De Sole A, et al. Increased interictal cerebral glucose metabolism in a cortical-subcortical netwok in drug naive patients with cryptogenic temporal lobe epilepsy. J Neuro Neurosurg Psychiatry 1995; 59: 427-31.
96. Van Bogaert P, Massager N, Tugendhaft P, et al. statistical parametric mapping of regional glucose metabolism in mesial temporal lobe epilepsy. Neuroimage 2002; 12: 129-38.
97. Gaillard WD, Kopylev L, Weinstein S, et al. Low incidence of abnormal (18)FDG PET in children with new-onset partial epilepsy: a propective study. Neurology 2002; 58: 717-22.
98. Matheja P, Kuvert T, Ludemann P, et al. Temporal hypometabolism at the onset of cryptogenic temporal lobe epilepsy. Eur J Nucl Med 2001; 28: 625-32.
99. Gaillard WD, White S, Malow B, et al. FDG-PET in children and adolescents with partial seizures: role in epilepsy surgery evaluation. Epilepsy Res 1995; 20: 77-84.
100. Markand ON, Salanova V, Worth R, Park HM, Wellman HN. Comparative study of interictal PET and ictal SPECT in complex partial seizures. Acta Neurol Scand 1997; 95: 129-36.
101. Coubes P, Awad IA, Antar M, Magdinec M, Sufka B. Comparison and spatial correlation of interictal HMPAO-SPECT and FDG-PET in intractable temporal lobe epilepsy. Neurol Res 1993; 15: 160-8.
102. Nagata T, Tanaka F, Yonrkura Y, et al. Limited value of interictal brain perfusion SPECT for detection of epileptic foci: high resolution SPECT studies in comparison with FDG-PET. Ann Nucl Med 1995; 9: 59-63.
103. Lamusuo S, Ruottinen HM, Knuuti J, et al. Comparison of (18F)FDG-PET, (99mTC)-HMPAO-SPECT, and (123I)-iomazenil-SPECT in localizing the epileptogenic cortex. J Neurol Neurosurg Psychiatry 1997; 63: 743-8.
104. Abou-Khalil BW, Siegel GJ, Sackellares JC, Gilman S, Hichwa R, Marshall R. Positron emission tomography studies of cerebral glucose metabolism in chronic partial epilepsy. Ann Neurol 1987; 22: 480-6.
105. Engel Jr J, Kuhl DE, Phelps ME, Crandall PH. Comparative localization of epileptic foci in partial epilepsy by PCT and EEG. Ann Neurol 1982; 12: 529-37.
106. Kim YK, Lee DS, Kim SK, et al. Differential features of metabolic abnormalities between medial and lateral temporal lobe epilepsy: Qauntitative analysis of (18)F-FDG PET using SPM. J Nucl Med 2003; 44: 1006-12.
107. Koutroumanidis M, Hennessy MJ, Seed PT, et al. Significance of interictal bilateral temporal hypometabolism in temporal lobe epilepsy. Neurology 2000; 54: 1811-21.
108. Lucignani G, Tassi L, Fazio F, et al. Double-blind stereo-EEG and FDG PET study in severe partial epilepsies: are the electric and metabolic findings related? Eur J Nucl Med 1996; 23: 1498-507.
109. Juhasz C, Chugani DC, Muzik O, et al. Electroclinical correlates of flumazenil and fluorodeoxyglucose PET abnormalities in lesional epilepsy. Neurology 2000: 825-35.
110. Lee SK, Yun CH, Oh JB, et al. Intracranial ictal onset zone in nonlesional lateral temporal lobe epilepsy on scalp ictal EEG. Neurology 2003; 61: 757-64.
111. Hong KS, Lee SK, Kim JY, Lee DS, Chung CK. Pre-surgical evaluation and surgical outcome of 41 patients with non-lesional neocortical epilepsy. Seizure 2002; 11: 184-92.
112. Duncan JS, Koepp MJ. PET: central benzodiazepine neuroreceptor mapping in localization-related epilepsies. Adv Neurol 2000; 83: 131-6.
113. Theodore WH. When is positron emission tomography really necessary in epilepsy diagnosis? Curr Opin Neurol 2002; 15: 191-5.
114. Choi JY, Kim SJ, Hong SB, Seo DW, Hong SC, Kim BT, Kim SE. Extratemporal hypometabolism on FDG PET in temporal lobe epilepsy as a predictor of seizure outcome after temporal lobectomy. Eur J Nucl Med Mol Imaging 2003; 30: 581-7.
115. Lee SK, Lee DS, Yeo JS, et al. FDG-PET images quantified by probabilistic atlas of brain and surgical prognosis of temporal lobe epilepsy. Epilepsia 2002; 43: 1032-8.
116. Swartz BE, Tomiyasu U, Delgado Escueta AV, Mandelkern M, Khonsari A. Neuroimaging in temporal lobe epilepsy: Test sensitivity and relationships to pathology and postoperative outcome. Epilepsia 1992; 33: 624-34.
117. Chee MWL, Morris III HH, Antar MA, et al. Presurgical evaluation of temporal lobe epilepsy using interictal temporal spikes and positron emission tomography. Arch Neurol 1993; 50: 45-8.
118. Knowlton RC, Laxer KD, Ende G, et al. Presurgical multimodality neuroimaging in electroencephalographic lateralized temporal lobe epilepsy. Ann Neurol 1997; 42: 829-37.
119. Won HJ, Chang KH, Cheon JE, et al. Comparison of MR imaging with PET and ictal SPECT in 118 patients with intractable epilepsy. Am J Neuroradiol 1999; 20: 593-9.
120. Nagarajan L, Schaul N, Eidelberg D, Dhawan V, Frase R, Labar DR. Contralateral temporal hypometabolism on positron emission tomography in temporal lobe epilepsy. Acta Neurol Scand 1996; 93: 81-4.
121. Rubin E, Dhawan V, Moeller JR, et al. Cerabral metabolic topography in unilateral temporal lobe epilepsy. Neurology 1995; 45: 2212-23.
122. Holmes MD, Kelly K, Theodore WH. Complex partial seizures. Correlation of clinical and metabolic features. Arch Neurol 1988; 45: 1191-3.
123. Yamamoto YL, Ochs R, Gloor P, et al. Pattern of rCBF and focal energy metabolism changes in relation to electroencephalographic abnormality in the inter-ictal phase of partial epilepsy. In: Badly-Moulinier M, Ingvar DH, Meldrum BS (eds.), Cerebral blood flow, metabolism and epilepsy. John Libbey Eurotext, London, 1984, p. 51-62.
124. Valk PE, Laxer KD, Barbaro NM, Knezevic S, Dillon WP, Budinger TF. High resolution (2.6 mm) PET in partial complex epilepsy associated with mesial temporal sclerosis. Radiology 1993; 186: 55-8.
125. Bouilleret V, Dupont S, Spelle L, Baulac M, Samson Y, Semah F. Insular cortex involvement in mesiotemporal lobe epilepsy: a positron emission tomography study. Ann Neurol 2002; 51: 202-8.
126. Dupont S, Bouilleret V, Hasboun D, Semah F, Baulac M. Functional anatomy of the insula: new insights from imaging. Surg Radiol Anat 2003; 25: 113-9.
127. Juhasz C, Nagy F, Watson C, et al. Glucose and 11C-flumazenil positron emission tomography abnormalities of thalamic nuclei in temporal lobe epilepsy. Neurology 1999; 53: 2037-45.
128. Sackellares JC, Siegel GJ, Abou-Khalil BW, et al. Differences between lateral and mesial temporal metabolism interictally in epilepsy of mesial temporal origin. Neurology 1990; 40: 1420-6.
129. Kim SK, Lee DS, Lee SK, Kim YK, Chung CK, Chung JK, Lee MC. Diagnostic performance of (18)F-FDG-PET and ictal (99mTc)-HMPAO SPECT in occipital lobe epilepsy. Epilepsia 2001; 42: 1531-40.
130. Merlet I, Garcia-Larrea L, Grégoire MC, Lavenne F, Mauguière F. Source propagation of interictal spikes in temporal lobe epilepsy. Correlations between spike dipole modelling and [18F] fluorodeoxyglucose PET data. Brain 1996: 377-92.
131. Pozo M, Pascau J, Rojo P, et al. Correlation between FDG PET data and EEG dipole modeling. Clin Positron Imaging 2002; 3: 173.
132. Hong SB, Han HJ, Roh SY, Seo DW, Kim SE, Kim MH. Hypometabolism and interictal spikes during positron emission tomography scanning in temporal lobe epilepsy. Eur Neurol 2002; 48: 65-70 (2002b).
133. Snead 3rd OC, Chen LS, Mitchell WG, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in pediatric epilepsy surgery. Pediatr Neurol 1996; 14: 98-107.
134. Theodore WH, Sato S, Kufta CV, Gaillard WD, Kelley K. FDG-positron emission tomography and invasive EEG: seizure focus detection and surgical outcome. Epilepsia 1997; 38: 81-6.
135. Koutroumanidis M, Binnie CD, Elwes RD, et al. Interictal regional slow activity in temporal lobe epilepsy correlates with lateral temporal hypometabolism as imaged with 18FDG PET: neurophysiological and metabolic implications. J Neurol Neurosurg Psychiatry 1998; 65: 170-6.
136. Dupont S, Semah F, Baulac M, Samson Y. The underlying pathophysiology of ictal dystonia in temporal lobe epilepsy: an FDG-PET study. Neurology 1998; 51: 1289-92.
137. Wunderlich G, Schuller MF, Ebner A, et al. Temporal lobe epilepsy with sensory aura: interictal glucose hypometabolism. Epilepsy Res 2000; 38: 139-49.
138. Muzik O, da Silva EA, Juhasz C, et al. Intracranial EEG versus flumazenil and glucose PET in children with extratemporal lobe epilepsy. Neurology 2000; 54: 171-9.
139. Radtke RA, Hanson MW, Hoffman JM, et al. Temporal lobe hypometabolism on PET: Predictor of seizure control after temporal lobectomy. Neurology 1993; 43: 1088-92.
140. Manno EM, Sperling MR, Ding X, et al. Predictors of outcome after anterior temporal lobectomy: positron emission tomography. Neurology 1994; 44: 2331-6.
141. Salanova V, Markand O, Worth R, et al. FDG-PET and MRI in temporal lobe epilepsy: relationship to febrile seizures, hippocampal atrophy and outcome. Acta Neurol Scand 1998; 97: 146-53.
142. Lamusuo S, Forss N, Ruottinen HM, et al. [18F]FDG-PET and whole-scalp MEG localization of epileptogenic cortex. Epilepsia 1999; 40: 921-30.
143. Newberg AB, Alavi A, Berlin J, Mozley PD, O'Connor M, Sperling M. Ipsilateral and contralateral thalamic hypometabolism as a predictor of outcome after temporal lobectomy for seizures. J Nucl Med 2000; 41: 1964-8.
144. Juhasz C, Chugani DC, Muzik O, et al. relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome. Neurology 2001; 56: 1650-8.
145. Isnard J, Guénot M, Ostrowsky K, Sindou M, Mauguière F. The role of the insular cortex in temporal lobe epilepsy. Ann Neurol 2000; 48: 614-23.
146. Engel Jr J, Kuhl DE, Phelps ME, Rausch R, Nuwer M. Local cerebral metabolism during partial seizures. Neurology 1983; 33: 400-13.
147. Peyron R, Le Bars D, Cinotti L, et al. Effects of GABA-A receptors activation on brain glucose metabolism in normal subjects and Temporal Lobe Epilepsy (TLE) patients. A Positron Emission Tomography (PET) study. Part I: Brain glucose metabolism is increased after GABA-A receptors activation. Epilepsy Res 1994; 19: 45-54.
148. Peyron R, Le Bars D, Cinotti L, et al. Effects of GABA-A receptors activation on brain glucose metabolism in normal subjects and Temporal Lobe Epilepsy (TLE) patients. A Positron Emission Tomography (PET) study. Part II: The focal hypometabolism is reactive to GABA-A agonist administration in TLE. Epilepsy Res 1994; 19: 55-62.
149. Griffith HR, Perlman SB, Woodard AR, et al. Preoperative FDG-PET temporal lobe hypometabolism and verbal memory after temporal lobectomy. Neurology 2000; 54: 1161-5.
150. Hong SB, Roh SY, Kim SE, Seo DW. Correlation of temporal lobe glucose hypometabolism with the Wada memory test. Epilepsia 2000; 41: 1554-9.
151. Salanova V, Markand O, Worth R. Focal functional deficits in temporal lobe epilepsy on PET scans and the intracarotid amobarbital procedure: comparison of patients with unitemporal epilepsy with those requiring intracranial recordings. Epilepsia 2001; 42: 198-203.
152. Cornford EM, Gee MN, Swartz BE, et al. Dynamic 18F-fluorodeoxyglucose positron emission tomography and hypometabolic zones in seizures; reduced capillary influx. Ann Neurol 1998; 43: 801-8.
153. Pfund Z, Chugani DC, Juhasz C, et al. Evidence for coupling between glucose metabolism and glutamate cycling usin FDG PET and 1H magnetic resonance spectroscopy in patients with epilepsy. J Cereb Blood Flow Metab 2000; 20: 871-8.
154. Henry TR, Babb TL, Engel Jr J, Mazziotta JC, Phelps ME, Crandall PH. Hippocampal neuronal loss and regional hypometabolism in temporal lobe epilepsy. Ann Neurol 1994; 36: 925-7.
155. Semah F, Baulac M, Hasboun D, et al. Is interictal temporal hypometabolism related to mesial temporal sclerosis? A positron emission tomography/magnetic resonance imaging confrontation. Epilepsia 1995; 36: 447-56.
156. O'Brien TJ, Newton MR, Cook MJ, et al. Hippocampal atrophy is not a major determinant of regional hypometabolism in temporal lobe epilepsy. Epilepsia 1997; 38: 74-80.
157. Dlugos DJ, Jaggi J, O'Connor WM, et al. Hippocampal cell density and subcortical metabolism in temporal lobe epilepsy. Epilepsia 1999; 40: 408-13.
158. Foldvary N, Lee N, Hanson MW, et al. Correlation of hippocampal neuronal density and FDG-PET in mesial temporal lobe epilepsy. Epilepsia 1999; 40: 26-9.
159. Choi D, Na DG, Byun HS, et al. White-matter change in mesial temporal sclerosis: correlation of MRI with PET, pathology and clinical features. Epilepsia 1999; 40: 1634-41.
160. Lamuosuo S, Jutila L, Ylinen A, et al. 18F-FDG-PET reveals temporal hymetabolism in patients with temporal lobe epilepsy even when quantitative MRI and histopathological analysis show only mild hippocampal damage. Arch Neurol 2001; 58: 933-9.
161. Theodore WH, Gaillard WD, De Carli C, Bhatia S, Hatta J. Hippocampal volume and glucose metabolism in temporal lobe epileptic foci. Epilepsia 2001; 42: 130-2.
162. Knowlton RC, Laxer KD, Klein G, et al. In vivo hippocampal glucose metabolism in me sial temporal lobe epilepsy. Neurology 2001; 57: 1184-90.
163. Latack JT, Abou-Khalil BW, Siegel GJ, Sackellares JC, Gabrielsen TO, Aisen AM. Patients with partial seizures: evaluation by MR, CT, and PET Imaging. Radiology 1986; 159: 159-63.
164. Diehl B, LaPresto E, Najm I, et al. Neocortical temporal FDG-PET hypometabolism correlates with temporal lobe atrophy in hippocampal sclerosis associated with microscopic cortical dysplasia. Epilepsia 2003; 44: 559-64.
165. Chassoux F, Semah F, Bouilleret V, et al. Metabolic changes and electro-clinical patterns in mesio-temporal lobe epilepsy: a correlative study. Brain 2004; 127: 164-74.
166. Rausch R, Henry TR, Ary CM, Engel Jr J, Mazziotta J. Asymmetric interictal glucose hypometabolism and cognitive performance in epileptic patients. Arch Neurol 1994; 51: 139-44.
167. Jokeit H, Seitz RJ, Markowitsch HJ, Neumann N, Witte OW, Ebner A. Prefrontal asymmetric interictal glucose metabolism and cognitive impairment in patients with temporal lobe epilepsy. Brain 1997; 120: 2283-94.
168. Salanova V, Morris 3rd HH, Rehm P, et al. Comparison of the intracarotid amobarbital procedure and interictal cerebral 18-fluorodeoxyglucose positron emission tomography scans in refractory temporal lobe epilepsy. Epilepsia 1992; 33: 635-8.
169. Hajek M, Wieser HG, Khan N, et al. Preoperative and postoperative glucose consumption in mesiobasal and lateral temporal lobe epilepsy. Neurology 1994; 44: 2125-32.
170. Régis et al. à compléter.
171. Spanaki MV, Kopylev L, DeCarli C, et al. Postoperative changes in cerebral metabolism in temporal lobe epilepsy. Arch Neurol 2000; 57: 1447-52.
172. Ryvlin P, Garcia-Larrea L, Philippon B, et al. High signal intensity on T2-weighted MRI correlates with hypoperfusion in temporal lobe epilepsy.
173. Ryvlin P, Coste S, Hermier M, Mauguiere F. Temporal pole MRI abnormalities in temporal lobe epilepsy. Epileptic Disord 2002; 4: S33-39.
174. Meiners LC, Witkamp TD, de Kort GA, et al. Relevance of temporal lobe white matter changes in hippocampal sclerosis. Magnetic resonance imaging and histology. Invest Radiol 1999; 34: 38-45.
175. Mitchell LA, Jackson GD, Kalnins RM, et al. Anterior temporal abnormality in temporal lobe epilepsy: A quantitative MRI and histopathologic study. Neurology 1999; 52: 327-36.
176. Colombo N, Tassi L, Galli C, et al. Focal cortical dysplasias: MR imaging, histopathologic, and clinical correlations in surgically treated patients with epilepsy. Am J Neuroradiol 2003; 24: 724-33.
177. Savic I, Swanborg E, Thorell JO. Cortical benzodiazepine receptor changes are relayed to frequency of partial seizures: a positron emission tomography study. Epilepsia 1996; 37: 236-44.
178. 11C-flumazenil PET in patients with refractory temporal lobe epilepsy and normal MRI. Neurology 2000; 54: 332-9.
179. Hammers A, Koepp MJ, Richardson MP, et al. Central benzodiazepine receptors in malformations of cortical development: A quantitative study. Brain 2001; 124: 1555-65.
180. Ryvlin P, Bouvard S, Le Bars D, Mauguière F. Transient and falsely lateralizing flumazenil-PET asymmetries in temporal lobe epilepsy. Neurology 1999; 53: 1882-5.
181. Hammers A, Koepp MJ, Labbe C, et al. Neocortical abnormalities of [11C]-flumazenil PET in mesial temporal lobe epilepsy. Neurology 2001; 56: 897-906.
182. Szelies B, Sobesky J, Pawlik G, et al. Impaired benzodiazepine receptor binding in peri-lesional cortex of patients with symptomatic epilepsies studied by [(11)C]-flumazenil PET. Eur J Neurol 2002; 9: 137-42.
183. Lamusuo S, Pitkanen A, Jutila L, et al. [11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology. Neurology 2000; 54: 2252-60.
184. Szelies B, Weber-Luxenburger G, Mielke R, et al. Interictal hippocampal benzodiazepine receptors in temporal lobe epilepsy: comparison with coregistered hippocampal metabolism and volumetry. Eur J Neurol 2000; 7: 393-400.
185. Hammers A, Koepp MJ, Hurlemann R, et al. Abnormalities of grey and white matter [11C]flumazenil binding in temporal lobe epilepsy with normal MRI. Brain 2002; 125: 2257-71.
186. Hammers A, Koepp MJ, Richardson MP, Hurlemann R, Brooks DJ, Duncan JS. Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. Brain 2003; 126: 1300-18.
187. Arnold S, Berthele A, Drzezga A, et al. Reduction of benzodiazepine receptor binding is related to the seizure onset zone in extratemporal focal cortical dysplasia. Epilepsia 2000; 41: 818-24.
188. Richardson MP, Friston KJ, Sisodiya SM, et al. Cortical grey matter and benzodiazepine receptors in malformations of cortical development. A voxel-based comparison of structural and functional imaging data. Brain 1997; 120: 1961-73.
189. Richardson MP, Koepp MJ, Brooks DJ, Duncan JS. 11C-flumazenil PET in neocortical epilepsy. Neurology 1998; 51: 485-92.
190. Francione S, Kahane P, Tassi L, Hoffmann D, Durisotti C, Pasquier B, Munari C. Stero-EEG of interictal and ictal electrical activity of a histologically proven heterotopic gray matter associated with partial epilepsy. Electroencephalogr Clin Neurophysiol 1994; 90: 284-90.
191. Mattia D, Olivier A, Avoli M. Seizure-like discharges recorded in human dysplastic neocortex maintained in vitro. Neurology 1995; 45: 1391-5.
192. Palmini A, Gambardella A, Andermann F, et al. Intrinsic epileptogenicity of human dysplastic cortex as suggested by corticography and surgical results. Ann Neurol 1995; 37: 476-87.
193. Sisodiya SM, Free SL, Thom M, Everitt AE, Fish DR, Shorvon SD. Evidence for nodular epileptogenicity and gender differences in periventricular heterotopia. Neurology 1999; 52: 336-41.